Main content

    Liver Cancer
    (Hepatoma / Hepatocellular Carcinoma / HCC)

    CPMC Cancer Services

    Oncology / Cancer Clinical Trials Main Page | Adult Clinical Trials Main Page

    Further protocol information can be found on the links below at ClinicalTrials.gov


    First Line Treatment  |  Second Line Treatment

    Active Trials

    First Line Treatment

    Title: A Randomized, Multi-center Phase III Study of Nivolumab Versus Sorafenib as First-Line Treatment in Patients With Advanced Hepatocellular Carcinoma (CheckMate 459: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 459)
    Description: The purpose of this study is to determine if nivolumab or sorafenib is more effective in the treatment of Advanced Hepatocellular Carcinoma
    Investigator: Ari Baron, MD
    Eligibility: Subjects 18 y/o and older, with histologically confirmed advanced hepatocellular carcinoma, not eligible for surgical and/or locoregional therapies; or progressive disease after surgical and /or locoregional therapies
    Status: Active and open to enrollment
    Contact: Brenda Eng, 415-600-1775, Email: EngB@cpmcri.org about Study BMS 459

    Back to top

    Active Trials

    Second Line Treatment

    Title: A Multicenter, Single Arm, Phase Ib/II Study to Evaluate Efficacy, Safety, and PK of MSC2156119J as Monotherapy in Subjects With MET+ Advanced Hepatocellular Carcinoma With Child Pugh Class A Liver Function Who Have Failed Sorafenib Treatment
    Description: his is a Phase 1b/2, multicenter, single arm trial to assess the efficacy, safety, and pharmacokinetics (PK) of MSC2156119J as monotherapy in subjects with MET+ advanced hepatocellular carcinoma (HCC) with child Pugh Class A liver function who have failed sorafenib treatment
    Investigator: Ari Baron, MD
    Eligibility: Subjects 18 y/o and older, with histologically or cytologically confirmed HCC
    Status: Active and open to enrollment
    Contact: Brenda Eng, 415-600-1775, Email: EngB@cpmcri.org about Study Merck EMR 200095-005

    Title: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Enzalutamide in Subjects With Advanced Hepatocellular Carcinoma
    Description: The purpose of the study is to evaluate the efficacy of enzalutamide in subjects with advanced hepatocellular carcinoma (HCC) as measured by overall survival (OS)
    Investigator: Jennifer Guy, MD
    Eligibility: Subjects 18 y/o and older, with a documented diagnosis of advanced HCC of any etiology
    Status: Active and open to enrollment
    Contact: Brenda Eng, 415-600-1775, Email: EngB@cpmcri.org about Study Astellas 9785-CL-3021

    Title: Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Ramucirumab and Best Supportive Care Versus Placebo and BSC as Second-Line Treatment in Patients With Hepatocellular Carcinoma and Elevated Baseline Alpha-Fetoprotein Following First-Line Therapy With Sorafenib
    Description: The purpose of this study is to evaluate the safety and efficacy of ramucirumab in participants with hepatocellular carcinoma (HCC) and elevated baseline alpha-fetoprotein
    Investigator: Ari Baron, MD
    Eligibility: Subjects 18 y/o and older, with a diagnosis of HCC based on histopathologic findings, or a diagnosis of cirrhosis and a tumor with classical HCC imaging characteristics
    Status: Active and open to enrollment
    Contact: Brenda Eng, 415-600-1775, Email: EngB@cpmcri.org about Study Lilly JVDE

    Title: A Phase 3, Randomized, Double-blind, Controlled Study of Cabozantinib (XL184) vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior Sorafenib
    Description: Study of Cabozantinib (XL184) vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior Sorafenib (CELESTIAL)
    Investigator: Ari Baron, MD
    Eligibility: Subjects 18 y/o and older, who have a Histological or cytological diagnosis of HCC
    Status: Active and open to enrollment
    Contact: Brenda Eng, 415-600-1775, Email: EngB@cpmcri.org about Study Exelixis:XL184-309

    • updated February 2016

    Back to top